WO2007073705A3 - Composiciones farmacéuticas que contienen la proteína nma0939 - Google Patents

Composiciones farmacéuticas que contienen la proteína nma0939 Download PDF

Info

Publication number
WO2007073705A3
WO2007073705A3 PCT/CU2006/000019 CU2006000019W WO2007073705A3 WO 2007073705 A3 WO2007073705 A3 WO 2007073705A3 CU 2006000019 W CU2006000019 W CU 2006000019W WO 2007073705 A3 WO2007073705 A3 WO 2007073705A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein nma0939
nma0939
pharmaceutical compositions
compositions containing
containing protein
Prior art date
Application number
PCT/CU2006/000019
Other languages
English (en)
French (fr)
Other versions
WO2007073705A2 (es
Inventor
Feyt Rolando Pajon
Garcia Gretel Sardinas
Castellanos Agustin Lage
Corona Daniel Yero
Diaz Darien Garcia
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Feyt Rolando Pajon
Garcia Gretel Sardinas
Castellanos Agustin Lage
Corona Daniel Yero
Diaz Darien Garcia
Blanco Sonia Gonzalez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Feyt Rolando Pajon, Garcia Gretel Sardinas, Castellanos Agustin Lage, Corona Daniel Yero, Diaz Darien Garcia, Blanco Sonia Gonzalez filed Critical Ct Ingenieria Genetica Biotech
Priority to AU2006331224A priority Critical patent/AU2006331224A1/en
Priority to EP06846929A priority patent/EP1977761A2/en
Priority to US12/097,895 priority patent/US20090208521A1/en
Priority to CA002633424A priority patent/CA2633424A1/en
Priority to BRPI0620867-3A priority patent/BRPI0620867A2/pt
Publication of WO2007073705A2 publication Critical patent/WO2007073705A2/es
Publication of WO2007073705A3 publication Critical patent/WO2007073705A3/es
Priority to NO20083318A priority patent/NO20083318L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de composiciones farmacéuticas que contienen la proteína NMA0939. Las composiciones de la presente invención confieren protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMA0939 se identificó como componente de las preparaciones de vesículas de membrana externa de Neisseria meningitidis, se obtuvo mediante la tecnología del ADN recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMA0939, las composiciones que la contienen poseen alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. Las composiciones de esta invención son aplicables en la medicina humana.
PCT/CU2006/000019 2005-12-29 2006-12-28 Composiciones farmacéuticas que contienen la proteína nma0939 WO2007073705A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2006331224A AU2006331224A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein NMA0939
EP06846929A EP1977761A2 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
US12/097,895 US20090208521A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
CA002633424A CA2633424A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
BRPI0620867-3A BRPI0620867A2 (pt) 2005-12-29 2006-12-28 formulações farmacêuticas que contêm a proteìna nma0939
NO20083318A NO20083318L (no) 2005-12-29 2008-07-28 Farmasoytiske sammensetninger inneholdende protein NMA0939

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2005-0279 2005-12-29
CU20050279A CU23549A1 (es) 2005-12-29 2005-12-29 Composiciones farmacéuticas que contienen la proteína nma0939

Publications (2)

Publication Number Publication Date
WO2007073705A2 WO2007073705A2 (es) 2007-07-05
WO2007073705A3 true WO2007073705A3 (es) 2007-09-13

Family

ID=38218331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2006/000019 WO2007073705A2 (es) 2005-12-29 2006-12-28 Composiciones farmacéuticas que contienen la proteína nma0939

Country Status (13)

Country Link
US (1) US20090208521A1 (es)
EP (1) EP1977761A2 (es)
KR (1) KR20080081198A (es)
CN (1) CN101443037A (es)
AR (1) AR058735A1 (es)
AU (1) AU2006331224A1 (es)
BR (1) BRPI0620867A2 (es)
CA (1) CA2633424A1 (es)
CU (1) CU23549A1 (es)
NO (1) NO20083318L (es)
RU (1) RU2008131066A (es)
WO (1) WO2007073705A2 (es)
ZA (1) ZA200805355B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180064801A1 (en) * 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066791A1 (en) * 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
WO2002079243A2 (en) * 2001-02-12 2002-10-10 Chiron Srl. Gonococcal proteins and nucleic acids
WO2004014418A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
WO2005054282A1 (es) * 2003-12-03 2005-06-16 Centro De Ingenieria Genetica Y Biotecnologia Proteína nmb0928 y su uso en formulaciones farmaceuticas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066791A1 (en) * 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
WO2002079243A2 (en) * 2001-02-12 2002-10-10 Chiron Srl. Gonococcal proteins and nucleic acids
WO2004014418A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
WO2005054282A1 (es) * 2003-12-03 2005-06-16 Centro De Ingenieria Genetica Y Biotecnologia Proteína nmb0928 y su uso en formulaciones farmaceuticas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARKHILL J ET AL: "COMPLETE DNA SEQUENCE OF A SEROGROUP A STRAIN OF NEISSERIA MENINGITIDIS Z2491", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 404, 30 March 2000 (2000-03-30), pages 502 - 506, XP000918875, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
AU2006331224A1 (en) 2007-07-05
CU23549B7 (es) 2010-07-20
WO2007073705A2 (es) 2007-07-05
RU2008131066A (ru) 2010-02-10
ZA200805355B (en) 2009-04-29
CU23549A1 (es) 2010-07-20
US20090208521A1 (en) 2009-08-20
EP1977761A2 (en) 2008-10-08
CA2633424A1 (en) 2007-07-05
KR20080081198A (ko) 2008-09-08
AR058735A1 (es) 2008-02-20
BRPI0620867A2 (pt) 2011-11-29
CN101443037A (zh) 2009-05-27
NO20083318L (no) 2008-09-26

Similar Documents

Publication Publication Date Title
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
WO2007149715A3 (en) Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
WO2010066418A8 (de) Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
DK2054431T3 (da) Konformere af bakterielle adhæsiner
DK2010563T3 (da) Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2007119011A9 (fr) Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2007112702A3 (es) Composición farmacéutica que comprende la proteína nmb0938
WO2007073705A3 (es) Composiciones farmacéuticas que contienen la proteína nma0939
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
WO2009077744A3 (en) Vaccines for brucellosis
WO2007112703A3 (es) Composición farmacéutica que comprende la proteína nmb0606
TH94299B (th) สูตรผสมทางเภสัชกรรมซึ่งมีโปรตีน nma0939
TH94299A (th) สูตรผสมทางเภสัชกรรมซึ่งมีโปรตีน nma0939
WO2007073706A3 (es) Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680049521.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2633424

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5465/DELNP/2008

Country of ref document: IN

Ref document number: 5489/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008580

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006331224

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006846929

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 570015

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020087018520

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008131066

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006331224

Country of ref document: AU

Date of ref document: 20061228

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006331224

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06846929

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12097895

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0620867

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080630

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)